matha_collins
  • Martha Carlin

    Chief Executive Officer
    The BioCollective

Martha Carlin is the CEO and Co-founder of The BioCollective (TBC). Ms. Carlin is a seasoned executive of both public and private companies. She is a self-trained citizen scientist who applied her business training in “systems thinking” to the problem of understanding chronic disease after learning her young husband had Parkinson’s Disease. In 2014, her studies drew her to the microbiome which connected the dots across the scientific spectrum of her studies. Carlin has applied her systems approach to the microbiome and human health to help companies and researchers across the research spectrum connect the dots faster through TBC’s unique marketplace concept.


bjrn_nielsen
  • Henrik Bjørn Nielsen

    Chief Scientific Officer
    Clinical-Microbiomics

H. Bjørn Nielsen, PhD, Chief Scientific Officer at Clinical-Microbiomics A/S, has since 2008 been a frontrunner in the field of microbiome research. His participation in the MetaHit consortium led to a series of important scientific papers describing the human gut microbiome, including his pioneering work on co-abundance binning of metagenomics data into metagenomic species, bacteriophages and other mobilegenetic elements. This year H. Bjørn has authored 4 papers published in Nature journals, including a three-pronged association study that links microbiome,serum metabolome and clinical data in pre-diabetic Danes and a study that reports on the largest metatranscriptomics date set to date. At Clinical-Microbiomics H. Bjørn heads the innovation with clients and the continued adaptation and development of new analysis concepts and methods.


tim_21
  • Tim Spector

    Professor of Genetic Epidemiology
    Kings College London

Tim Spector is a Professor of GeneticEpidemiology and Director of the TwinsUK Registry at Kings College, London. He trained originally inrheumatology and epidemiology. In 1992 he moved into genetic epidemiology andfounded the UK Twins Registry, of 13,000 twins, which is the richest collectionof genotypic and phenotypic information worldwide. He is past President of theInternational Society of Twin Studies, directs the European Twin RegistryConsortium (Discotwin) and collaborates with over 120 centres worldwide. He has demonstrated the genetic basis of a wide range ofcommon complex traits, many previously thought to be mainly due to ageing andenvironment. Through genetic association studies (GWAS), his group have foundover 500 novel gene loci in over 50 disease areas. He has published over800 research articles and is ranked as being in the top 1% of the world’s most citedscientists by Thomson-Reuters as well as the most cited scientist at King’sCollege London. He held a prestigious European Research Council seniorinvestigator award in epigenetics and is a NIHR Senior Investigator and is aFellow of the UK Academy of Medical Sciences. His current work focuses on omicsand the microbiome and directs the crowdfunded British Gut microbiome project. He is a prolific writer with severalpopular science books and a regular blog, focusing on genetics, epigenetics andmost recently microbiome and diet (The Diet Myth). He is in demand as a publicspeaker and features regularly in the media.


dr_thomas_kuri
  • Dr Thomas Kuri

    Scientific Director
    Zymo Research Europe

Thomas graduated with a PhD in Virology in 2008, followed by Post-Doc positions at the department of Virology at IMMH in Freiburg, Germany and Karolinska Institutet in Stockholm, Sweden. Main focus of his research was the interaction of viruses with the innate immune system. In 2013 he joined Zymo Research to build the R&D department for its European location in Germany.


Jennie Smolly Caruthers Biotech Building lab at the University of Colorado Boulder. (Photo by Casey A. Cass/University of Colorado)
  • Professor Rob Knight

    Principle Investigator
    Department of Pediatrics, University of California San Diego

Rob Knight is a Professor in the Department of Pediatrics, with an additional appointment in the Department of Computer Science, at the University of California San Diego. He was chosen as one of 50 HHMI Early Career Scientists in 2009, is a Senior Editor at the ISME Journal, a member of the Steering Committee of the Earth Microbiome Project, and a co-founder of the American Gut Project.


headshot
  • Dr Trevor Lawley

    Group Leader
    Host-Microbiota Interactions Laboratory, Wellcome Trust Sanger Institute

Trevor obtained his PhD from the University of Alberta, Canada, where he studied the mechanisms that pathogenic bacteria use to disseminate antibiotic resistance genes. In 2010, Trevor was appointed as a Career Development Fellow in the Sanger Institute Faculty and was promoted to Group Leader in 2014. He receives funding from the Medical Research Council. Trevor’s research investigates the mechanisms that underlie how micro-organisms on mucosal surfaces (gut, nasopharnyx, uro-gential tract) interact with their host during periods of health and disease. In particular, he seeks to develop novel ways to treat diseases that are associated with unwanted imbalances in the micro-organism communities.


head
  • Professor Peer Bork

    Senior Bioinformatics Group Leader
    EMBL

Professor Peer Bork is senior group leader and joint head of the Structural and Computational Biology unit at EMBL, a European research organization with headquarters in Heidelberg where he also serves as strategic head of bioinformatics. In addition, he holds an appointment at the Max-Delbrück-Center for Molecular Medicine in Berlin. Dr. Bork co-founded five successful biotech companies, two of which went public. More than 35 of his former associates now hold professorships or other group leader positions in prominent institutions all over the world. He received the “Nature award for creative mentoring” for his achievements in nurturing and stimulating young scientists and was recipient of the prestigious “Royal Society and Académie des Sciences Microsoft award” for the advancement of science using computational methods.  Dr. Bork obtained two competitive ERC advanced investigator grants and is elected member of both the German national academy of sciences (Leopoldina) and the European molecular biology organization (EMBO).


head
  • Professor Dusko Ehrlich

    Head of Research and Founder of GM
    INRA

Stanislav Dusko EHRLICH was trained in Organic Chemistry at the University of Zagreb, Croatia and obtained PhD degree in Biochemistry at the University Paris VII, France. He was a research associate of Dr. Joshua Lederberg, Nobel Prize winner, in the Department of Genetics, Stanford University Medical School, California. He founded and directed Microbial Genetics Research Unit and the Microbiology Department at the National Institute for Agricultural Research (INRA).  He also founded a start-up company Enterome, developing microbiome-based biomarkers. He is Research Director Emeritus at INRA, Professor at King’s College London and Chief Scientific Officer of Enterome.  His research interests are in Human Microbiome; he coordinated the EU-funded project MetaHIT and is the PI of the French Government Investissement d’Avenir 19 M€ grant MetaGenopolis. He authored or co-authored over 330 publications in peer-reviewed scientific journals, 50 book chapters and 10 patents and holds an H index of 71. He is laureate of the career INRA Excellence of the Agricultural Research Award and winner of the Grand Prix del Duca of the French Academy for microbiome research, member of the French Academy of Agriculture, Croatian Academy of Sciences and Arts, the European Molecular Biology Organisation and the American Academy of Microbiology and is Chevalier de l’Ordre National du Mérite and Légion d’Honneur.


head
  • Professor Max Nieuwdorp

    Professor of internal medicine and diabetes
    AMC Amsterdam

Dr Nieuwdorp is currently working as an internist-endocrinologist and Head of the department of Experimental Vascular Medicine at the Academic Medical Centre (AMC) within the University of Amsterdam. He has initiated a translational research group focused on dissecting the causal role of (small) intestinal bacterial strains to reverse insulin resistance, adipose tissue inflammation and cardiovascular disease. Dr Niuewdorp is also Visiting Professor at the University of Gothenburg. He has previously completed a residency in internal medicine and a fellowship at AMC Amsterdam and a postdoctoral fellowship in glycobiology at University College San Diego, USA.


headshot
  • Dr Larry Weiss

    Chief Medical Officer
    AOBiome

Larry Weiss MD is the Chief Medical Officer at AOBiome. He has an extensive background in natural products chemistry, microbiology, clinical medicine, and pharmaceutical development and commercialization. Dr. Weiss is board certified in Anesthesiology, has an MD from Stanford University Medical School, and a BS from Cornell University in Biochemistry. He has a number of patents and is published in the areas of chemistry, electrophysiology, and microbiology.  Dr. Weiss is the founder of CleanWell Company. 


Wade-223
  • Professor William Wade

    Professor of Oral Microbiology
    Barts and The London School of Medicine and Dentistry

Professor Wade specialises in the molecular characterisation of the oral microbiome in health and disease, and the development and evaluation of antimicrobials and probiotics for the prevention and treatment of oral diseases. Beyond the UK, he is an Honorary Research Investigator at the Forsyth Institute, Cambridge, USA. Having graduated from the University of East Anglia in 1978 and completing a PhD in Oral Microbiology at Cardiff Dental School, he held lectureships in Cardiff and the University of Bristol before becoming Professor of Oral Biology at King’s College, London.


Patrick_Veiga
  • Patrick Veiga

    Gut Microbiota Research Program Co-leader Life Science Department
    Danone Research

Patrick Veiga, PhD joined Danone Nutricia Research in 2008 to participate in launching the newly created Gut microbiota team. Since then, Patrick has been leading internal research as well as collaborations with academic partners that aimed to understand the potential interplay between probiotics, gut microbiota and the host. Part of this work was published in international peer-reviewed journals including Nature, PNAS and ISME J. In 2011, he was assigned as a visiting scientist at the laboratory of the Prof. Wendy Garrett at Harvard School of Public Health (Boston, MA) where he spent 3 years. In 2014, Patrick re-integrated the Danone R&D Center in Palaiseau (France) where he is co-leading the Gut Microbiota Science Program for the Danone Dairy division.


headshot
  • Professor Jeroen Raes

    Group Leader
    KULeuven

Jeroen Raes is group leader of the Bioinformatics and (eco-)Systems Biology (BSB) research group at VIB in Brussels. He has an extensive track record in meta-omics and microbiome research. He is associate editor for ISME journal, Scientific Reports (Nature publishing group), SIGS and Genomics Insights and is reviewer and/or committee member for ANR/NWO/FWO/ERC proposals.The Raes lab combines large-scale, next-generation sequencing with novel computational approaches to investigate the functioning and variability of the healthy human microbiome at the systems level and studies its alteration in disease.


julian
  • Professor Julian Marchesi

    Professor of Human Microbiome Research
    Cardiff University

Julian Marchesi graduated from Cardiff University with a PhD in biochemistry (1992) and became interested in the role bacteria play in ecosystem function. During his post-doctoral years he developed an interest in the contribution of uncultured microbes to the maintenance and function of ecosystems i.e. molecular microbial ecology. He subsequently secured a Wellcome Trust Fellowship which extended his molecular microbial ecology interest and investigated, with culture independent methods, the diversity and distribution of genes involved in biodegradation of priority pollutants in pristine environments. After a short time investigating the deep biosphere he obtained a Lectureship (2001) in the Department of Microbiology, University College Cork, Ireland where he transferred these “omic” skills into the human gut and started to investigate the human gut ecosystem in health and disease. After 7 years in UCC, he moved back to Cardiff University in 2008 to a senior lectureship, where he investigates the role of the gut microbiome in maintaining host health and initiating diseases not only of the gut, but throughout the host system.  In 2013 he was promoted to Reader and also took a half time Readership in Digestive Health at Imperial College London.


Johan_head
  • Johan E.T. van Hylckama Vlieg

    Vice President Microbiome & Human Health Innovation
    Chr. hansen A/S


KyleX1
  • David Kyle

    CEO
    BioSystems Inc.

Dr Kyle has been CEO of Evolve BioSystems Inc. since 2014. The company is focused on changing the standard of care of babies based on new understandings of the interrelationship between the baby, the baby’s microbiome, and mother’s milk. He previously acted as an advisor to bio-tech start-ups through the DJK Consulting, a firm he founded in 2010 after founding two biotech businesses of his own; Martek Biosciences and Advanced BioNutrition Corp. He has a PhD in Lipid Biochemistry from the University of Alberta and, in 2009, was inducted into the US Space Technology Hall of Fame for his contributions to science and industry.


head
  • Professor Simon Kroll

    Professor of Medicine
    Imperial College

After reading Chemistry at Oxford, Simon Kroll completed undergraduate medical training at Oxford University Medical School, qualifying in 1980.  His initial paediatric training was at Oxford, working under the mentorship of David Baum and Peter Tizard.  After MRCP(UK), a short spell in Infectious Diseases at Great Ormond Street led to a Clinical Lectureship, and later a University Lectureship, in Richard Moxon’s Department in Oxford, where during tenure of a Lister Institute Research Fellowship he gained his first consultant post – in Paediatric Infectious Diseases – in 1988.  In 1993 he moved to Imperial College and St Mary’s Hospital as Professor of Paediatrics and Molecular Infectious Diseases.  He was elected FRCP in 1995, FRCPCH in 1997 and Fellow of the Academy of Medical Sciences in 2001. 
The activities of his research group (the Molecular Infectious Diseases Group, MIDG, established with Paul Langford) have focused on the genetic and molecular basis for the virulence of bacterial pathogens, in particular Haemophilus influenzae and Neisseria meningitidis, responsible for life-threatening infections such as meningitis and septicaemia in previously healthy children.  He has published over 100 papers in scientific journals on these and related topics.  


Michael_Cox
  • Dr Michael Cox

    Research Associate
    Imperial College London

Michael is a Research Associate in the Molecular Genetics and Genomics Group, in the Genomic Medicine Section of the National Heart and Lung Institute. He is a microbial ecologist by training, originally working on the functional ecology of marine microorganisms using mainly molecular techniques.
Currently, he is using high throughput sequencing in order to identify changes in microbial assemblages in the respiratory tract in a wide range of diseases.  These include chronic diseases such as cystic fibrosis, non-cystic fibrosis bronchiectasis, and asthma, as well as a acute infection such as cases of H1N1 pandemic flu and other viral infections.


n-a-img
  • Dr David MacIntyre

    Fellow in Reproductive Systems Medicine
    Imperial College London

Dr David MacIntyre’s research investigates the role of inflammation in the onset of term and preterm human labour. He is particularly interested in understanding the implications of the vaginal microbiome in poor pregnancy outcomes such as preterm premature rupture of membranes (PPROM), which is also known as when a woman’s waters break early during her pregnancy. His research team approaches this using both classical biochemistry methods as well as a “systems” approach where data acquired from genomic, transcriptomic and metabolic profiling platforms are integrated and modelled to investigate the interaction between vaginal microbiota and the maternal host. It is hoped that will lead to improved diagnostic and predictive tools that will assist in patient stratification and ultimately, improved pregnancy outcomes.


head
  • Dr James Kinross

    Senior Lecturer in Colorectal Surgery
    Imperial College London

Dr. James Kinross is a consultant colorectal surgeon, at St. Mary’s Hospital London. His clinical interests are in minimally invasive and laparoscopic surgery for the treatment of colorectal cancer. He also has an interest in surgical nutrition and modulation of the gut microbiota by pro and prebiotics for improved operative outcomes. He was trained in Northwest London, and he was an NIHR Clinical Lecturer in Surgery and an Ethicon Laparoscopic Fellow in Colorectal Surgery. He was awarded a Royal College of Surgeons of England training fellowship during his PhD and he was funded by the Academy of Medical Sciences as an early stage lecturer. He is a visiting Professor at the Royal College of Surgeons of Ireland. He is currently funded by Bowel and Cancer research and the Imperial BRC.


head
  • Professor David Berry

    Associate Professor Microbial Ecology
    University of Vienna

David Berry is Associate Professor at the University of Vienna. His research interests include:

  • Function of the intestinal microbiota in health and disease
  • Numerical approaches to study microbial communities 
  • Development of molecular and isotope-labeling methods for studying uncultivated microorganisms in their natural environment

He has 28 publications in peer-reviewed journals, including in leading multidisciplinary and discipline-specific journals such as: Proc Natl Acad Sci USA, Cancer Res, FEMS Microbiol Rev, and ISME J.


head
  • Dr Nick Ilott

    Post-Doctoral Researcher
    Kennedy Institute of Rheumatology

Nick’s interests lie in the interplay between the host and commensal microbes of the gut in the context of inflammation. Inflammation is capable of driving changes in the gut niche that may lead to expansion of bacterial taxa or changes in microbial function that reflect adaptive advantage to the inflamed environment. These changes are likely to feedback onto the immune system to promote either exacerbation or resolution of disease. To explore these host-microbe relationships he is using a variety of high-throughput methods (microarrays, Next Generation Sequencing) in functional genomics and metagenomics analyses. His scientific research is tied in with his interest in employing cutting-edge sequencing technologies from Illumina short-read sequencing to the latest in long-read sequencing – Oxford Nanopore MinION platform.


headshot
  • Dr Paul Wilmes

    Associate Professor of Systems Ecology
    Luxembourg Centre for Systems Biomedicine

Paul Wilmes earned his PhD from the School of Environmental Sciences at the University of East Anglia (UK) in 2006. For part of his doctoral research, he spent time at the Max Planck Institute for Marine Microbiology in Bremen (Germany). Paul subsequently carried out postdoctoral research at the University of California, Berkeley from where he returned in 2010 to his native Luxembourg through the ATTRACT fellowship scheme of the Luxembourg National Research Fund. Paul is currently Associate Professor of Systems Ecology at the Luxembourg Centre for Systems Biomedicine of the University of Luxembourg, where he heads the Eco-Systems Biology research group. Paul’s main research focus is on using Systems Biology approaches for unraveling fundamental ecological relationships within and between microbial populations in situ. His group has developed appropriate wet- and dry-lab methodologies for carrying out systematic molecular measurements of microbial consortia over space and time. This allows for example to define lifestyle strategies of distinct populations and link these to genetic and functional traits. The same approaches are allowing the study of microbiome-host molecular interactions. In this context, his group has also recently developed a microfluidics-based in vitro model of the human-microbial gastrointestinal interface called HuMiX.


headshot
  • Dr Lindsay Hall

    Research Leader
    Institute of Food Research, UEA

Lindsay Hall qualified with a BSc (Hons) in Microbiology from the University of Glasgow in 2003. She went on to study for a PhD in Microbiology and Immunology at the Wellcome Trust Sanger Institute. In 2013 Lindsay was awarded a 5 year Wellcome Trust New Investigator Award and is building her research team. The Hall lab’s research focus involves defining the complex interactions of the host with the intestinal microbiota and pathogens at mucosal surfaces. More specifically the group is focussed on how the dominant early life microbiota genus Bifidobacterium interacts with the host including; how these pioneer bifidobacteria colonise the gut (via surface structures and diet impacts [breast vs. formula milk]) and subsequently modulate immune function, including critical infection resistance and chronic inflammation, to understand how early life antibiotic-induced disturbances alter this microbial community, ultimately leading to a breakdown in pathogen protection and induction of inflammation. Another key goal is to identify bifidobacterial communities and their components that can restore a disturbed early life microbiota back into one able to promote health.


head-3
  • Greg Sieczkiewicz

    Chief IP Counsel
    MPM Capital

Greg Sieczkiewicz, J.D., Ph.D., joined MPM in 2015. Greg serves as Chief IP Counsel at several MPM portfolio companies. Prior to joining MPM, Greg was the architect of IP strategy of over a dozen venture-backed life sciences companies across the spectrum—from nucleic acid therapeutics, oral biologics, the microbiome, oncology, to protein engineering. Starting in 2009, Greg was Vice President, IP at Flagship Ventures. Earlier in his career, Greg practiced patent counseling and enforcement at national law firms Mintz Levin, Proskauer Rose and Foley Hoag. Greg completed his post-doctoral fellowship at the National Cancer Institute. He graduated from the College of the Holy Cross with an A.B. in Biology, received his Ph.D. in Cell, Molecular and Developmental Biology from Tufts University School of Medicine and graduated magna cum laude from the evening program of Suffolk University Law School. Greg is a member of the bar of the Commonwealth of Massachusetts and is admitted to practice before the United States Patent and Trademark Office. Greg is the current President of the Boston Patent Law Association.


head
  • Professor Morten Sommer

    Group Leader, Novo Nordisk Foundation Center for Biosustainability
    Technical University of Denmark

Morten got his Masters (University of Copenhagen) in Physics and Biophysics and his PhD (Harvard University) in Biophysics. During his PhD he became fascinated by bacteria and the incredibly biological diversity they comprise. He began to study their potential for harm (antibiotic resistance and bacterial pathogens) as well as their potential for addressing some of the societal challenges (biobased production of chemicals and synthetic biology). Since 2010, he has been a professor in systems biology (Technical University of Denmark), where his lab works on improving our understanding of bacterial systems in order to address challenges within healthcare and industrial biotechnology.


head
  • Majdi Osman

    Clinical Program Director
    OpenBiome

Majdi is the Clinical Program Director at OpenBiome. He is an Internal Medicine physician who trained at University College London.  He previously worked at the World Health Organization and completed his Master’s in Public Health at the Harvard T.H.Chan School of Public Health on a Frank Knox Fellowship.  He was trained in tropical medicine and infectious diseases at the London School of Hygiene and Tropical Medicine (LSHTM) and has taught and practiced medicine throughout Africa.  He co-founded YBank, a non-profit dedicated to adolescent health. His research focuses on infectious diseases, quality improvement and clinical safety.  He is excited to be part of OpenBiome in its mission to deliver safe access to FMT.


head
  • Dr David Cook

    Chief Scientific Officer
    Seres

David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics, Inc. (“Seres”). He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Prior to joining Seres, he served as the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization. Prior to IAVI, Dr. Cook was the founding CEO at Anza Therapeutics, a biotechnology startup that focused on developing a microbial vaccine platform to induce cellular immune responses. Before launching Anza, Dr. Cook held positions of increasing responsibility at the biotechnology corporations Cerus and Eligix, overseeing R&D, program management, manufacturing, and clinical and regulatory affairs. He has led teams in the development and commercialization of several biotech products and has been directly responsible for obtaining marketing authorization from the European Union for four medical products. Dr. Cook is also a co-inventor on more than 25 patents. He earned his undergraduate degree from Harvard College and his Ph.D. in chemistry from the University of California, Berkeley.


head
  • Denise Kelly

    Investment Advisor
    Seventure

Denise joined Seventure in September 2015 as an investment Advisor to the Life Sciences Team for microbiome field.

Her focus is in Human Microbiome Research and her time is dedicated to coverage of scientific and academic community on behalf of Seventure, and to prospect new investment opportunities in the specific field of microbiome.

Denise is currently based in Aberdeen, Scotland. Prior to joining Seventure, Denise was Head of her Research team at the World-renowned Rowett Institute, University of Aberdeen, where she acquired over 20 years experience in gut microbiology and immunology. She was the (former) Founder Director, CEO and CSO of GT Biologics Ltd, one of the first translational spinouts, developing Innovative Microbiome-based Therapies.


Alan-Walker3
  • Professor Alan Walker

    Senior Lecturer
    University of Aberdeen

Alan Walker is a microbiologist by training with specific interests in the bacteria that inhabit the gastrointestinal tracts of mammalian hosts, particularly in humans and mice. After receiving a BSc (Hons) in Microbiology from the University of Aberdeen he studied for his PhD at the Rowett Institute of Nutrition and Health and at the University of Dundee, specialising in gut microbiology and the role that intestinal bacteria play in the breakdown of dietary fibre. Following his PhD he spent eight years at the Wellcome Trust Sanger Institute in Cambridge, a world-leading centre for genomic research, before moving to his current post as a Senior Lecturer/Principal Investigator at the University of Aberdeen. His current research uses a combination of state of the art anaerobic culturing and DNA sequencing techniques to better characterise gut microbial communities and shed light on the roles these microbes play both in health and in disease.


head
  • Professor Dirk Haller

    Chair of nutrition and immunology
    Technical University of Munich

Prof. Haller conducts research in the field of nutritional science. His aim is to gain a better understanding of the biomedical effects of nutritional factors and bacteria on chronic diseases with an inflammatory origin. Research is focused on the intestine as an immunologically active interface.
After studying both nutrition science and food technology at the University of Hohenheim, Prof. Haller completed his doctorate (1999) in microbiology and nutrition science. Following periods of research in Switzerland (Nestlé Forschungszentrum) and the USA (University of North Carolina), he received an Emmy Noether scholarship from the German Research Foundation (DFG) to work at TUM. He received offers of Chairs from Canada (University of Alberta) and Switzerland (Swiss Federal Institute of Technology Zurich), but chose to accept the Chair of Food Biofunctionality at TUM’s Weihenstephan campus. Prof. Haller currently chairs the European Science Foundation’s (ESF) Forward Look initiative on “Gene environment interaction in chronic disease (GENESIS)”. He is Director of the Department of Nutrition and Food Science. Professor Haller now coordinates the national priority program of the German Research Foundation (DFG) on “intestinal microbiota” and heads a DFG graduate program in the Department of Nutritional Sciences at the Weihenstephan campus.


Janneke
  • Prof Janneke Van De Wijgert

    Professor of Infection and Global Health
    University of Liverpool

Janneke is a translational infectious disease researcher, educated in medical biology, public health epidemiology and medicine, and with work experience in clinical epidemiological research, laboratory research, and product development. The focus of her research has been prevention, diagnosis and treatment of HIV and other sexually transmitted infections (STI), including GCP-compliant clinical trials of new prevention technologies, evaluation of novel rapid diagnostics, and research on the cervicovaginal microbiome and mucosal immunology. She has published more than 100 papers in peer-reviewed journals and books.


head
  • Dr Debby Bogaert

    Professor of Paediatric Immunology
    UMC Utrecht

Dr. Bogaert is a physician scientist who heads a translation research group working on pathogenesis, treatment and prevention of respiratory tract infections, studied from an ecological perspective. 
Since 2009 she has initiated several ecological studies of the upper respiratory tract microbiome in relation to pathogenesis of respiratory infections. She received several grants including a Veni and Vidi grant (NWO) and Top grant (ZonMW) to develop and use a metagenomic pipeline for analysis of low-density respiratory microbiota. Together with multiple collaborators she executed molecular epidemiological studies to identify drivers and ecological mechanisms of respiratory infections, as well as to study the magnitude of side effects of broad spectrum antibiotics on the microbiome development and AMR gene selection in new borns. 
Since January 2016 she also became active within the UK, joining the new Florey Institute with the aim to actively support integrative research on pathogenesis of respiratory diseases in healthy and chronically ill patient groups.


Floris_Imhann
  • Floris Imhann

    Gut Microbiome Researcher
    University Medical Center Groningen

Floris Imhann graduated from the University of Groningen medical school in 2011. During his studies at the age of 20, he founded an eHealth company. After leaving business, he started his PhD focussing on the influence of gut microbiota on Inflammatory Bowel Disease (IBD). Floris is part of the research group of Prof. Rinse Weersma that investigates both the host and the microbial genetics of gut diseases at the Gastroenterology Department of the University Medical Center Groningen, The Netherlands. Floris works closely together with the microbiome researchers of the group of Prof. Cisca Wijmenga. He recently published his findings on the large effects of proton pump inhibitors on the gut microbiota.


headshot
  • Dr Manimozhiyan Arumugam

    Group Leader and Associate Professor
    University of Copenhagen

Dr. Arumugam received his PhD in computational biology from the European Molecular Biology Laboratory (Heidelberg) in 2010. At the Metabolic Genetics section of the Center, he studies the trillions of microbes that inhabit the human gut, collectively called the human gut microbiota. As part of the European MetaHIT consortium, he has contributed to major advances in understanding the human gut microbiome (collective genomes of the human gut microbiota), including the establishment of the first human gut microbial gene catalog and the discovery of enterotypes. He believes that our health and diseases are strongly influenced by our genetics, by the environment we live in, and by our gut microbiome. His research is thus interdisciplinary, combining metagenomics (a technique to study the gut microbiome), (epi)genomics, (epi)genetics, (meta)transcriptomics, and metabolomics. Arumugam group investigates the role of gut microbiome in multiple sclerosis, type 2 diabetes and obesity. The group also has international collaborations studying the interaction between the gut microbiome and the host in the context of several other diseases, including cardio-metabolic diseases, chronic liver diseases and cancer


bruce_roberts
  • Bruce Roberts

    Chief Scientific Officer
    Vedanta

Dr. Roberts has 30 years of experience in biotechnology and pharmaceutical drug discovery and development. He most recently served as head of Neuro-Immunology and Immune-Mediated Disease Research at Sanofi Genzyme where he directed pre-clinical efforts resulting in the introduction of therapeutic antibodies, gene therapies, cell therapies and small molecules into multiple clinical trials for the treatment of cancer, multiple sclerosis and autoimmunity. He directed research efforts in support of several approved products. He has authored more than fifty peer-reviewed publications and contributed to several issued patents and patent applications.